Oral toxicity and pharmacokinetic studies of SHetA2, a new chemopreventive agent, in rats and dogs

References

• Banerjee, A., Frost, K., Thomas, S., Metcalfe, P., Kapetanovic, I. M., Lyubimov, A. V. (2010). Development of more bioavailable orally absorbed chemopreventive agents from leads derived from natural sources: potential challenges. Presented at the 49th Annual Meeting of the Society of Toxicology, March 7–11, 2010, Salt Lake City, Utah, USA.
   Google Scholar
• Benbrook, D. M., Madler, M. M., Spruce, L. W., Birckbichler, P. J., Nelson, E. C., Subramanian, S., et al. (1997). Biologically active heteroarotinoids exhibit anticancer activity and decreased toxicity. J Med Chem 40:3567–3583.
   PubMed Web of Science ®Google Scholar
• Benbrook, D. M. (2002). Refining retinoids with heteroatoms. Minirev Med Chem 2:271–277.
   Google Scholar
• Benbrook, D. M., Kamelle, S. A., Guruswamy, S. B., Lightfoot, S. A., Rutledge, T. L., Gould, N. S., et al. (2005). Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists. Inv New Drugs 23:417–428.
   PubMed Web of Science ®Google Scholar
• Benbrook, D. M., Lightfoot, S., Ranger-Moore, J., Liu, T., Chengedza, S., Berry, W. L., Dozmorov, I. (2008). Gene expression analysis of biological systems driving an organotypic model of endometrial carcinogenesis and chemoprevention. Gene Regul Syst Biol 2:21–42.
   PubMedGoogle Scholar
• Chengedza, S., Liu, T., Benbrook, D. M. (2007). SHetA2 effects on thymidine phosphorylase and NF-κB activity. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 22–26, 2007, San Francisco, California, USA.
   Google Scholar
• Chengedza, S., Benbrook, D. M. (2010). NF-kappaB is involved in SHetA2 circumvention of TNF-alpha resistance, but not induction of intrinsic apoptosis. Anticancer Drugs 21:297–305.
   PubMed Web of Science ®Google Scholar
• Chun, K. H., Benbrook, D. M., Berlin, K. D., Hong, W. K., Lotan, R. (2003). The synthetic heteroarotinoid SHetA2 induces apoptosis in squamous carcinoma cells through a receptor-independent and mitochondria-dependent pathway. Cancer Res 63:3826–3832.
   PubMed Web of Science ®Google Scholar
• Dawson, M. I., Fontana, J. A. (2010). The peptidomimetic, 1-adamantyl-substituted, and Flex-Het classes of retinoid-derived molecules: structure-activity relationships and retinoid receptor-independent anticancer activities. Mini Rev Med Chem 10:455–491.
   Google Scholar
• Guruswamy, S., Lightfoot, S., Gold, M., Hassan, R., Berlin, K. D., Ivey, R. T., Benbrook, D. M. (2001). Effects of retinoids on cancerous phenotype and apoptosis in organotypic culture of ovarian carcinoma. J Nat Cancer Inst 93:516–525.
   PubMed Web of Science ®Google Scholar
• Hyde, J., Benbrook, D. M. (2006). Sensitivities of uterine adenocarcinoma, mixed mullerian tumor (MMT) and sarcoma cell lines to chemotherapeutic agents and a Flex-Het drug. Am J Pharmacol Toxicol 1:83–86.
   PubMedGoogle Scholar
• Kabirov, K. K., Kapetanovic, I. M., Lindeblad, M., Zakharov, A., Benbrook, D. M., Lyubimov, A. V. (2010). Preclinical toxicology assessment of SHetA2, a novel chemopreventive agent, in rats and dogs. Presented at the 49th Annual Meeting of the Society of Toxicology, March 7–11, 2010, Salt Lake City, Utah, USA. The Toxicologist 114:153.
   Google Scholar
• Lin, Y., Liu, X., Yue, P., Benbrook, D. M., Berlin, K. D., Khuri, F. R., et al. (2008). Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells. Mol Cancer Ther 7:3556–3565.
   PubMed Web of Science ®Google Scholar
• Liu, S, Brown, C. W., Berlin, K. D., Dhar, A., Guruswamy, S. B., Brown, D., et al. (2004). Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells. J Med Chem 47:999–1007.
   PubMed Web of Science ®Google Scholar
• Liu, T, Masamha, CP, Chengedza, S, Berlin, KD, Lightfoot, S, He, F, et al. (2009). Development of flexible-heteroarotinoids for kidney cancer. Mol Cancer Ther 8:1227–1238.
   PubMed Web of Science ®Google Scholar
• Liu, T.-Z., Hannafon, B., Gill, L., Kelly, B., Benbrook, D. M. (2007). Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria. Mol Cancer Ther 6:1814–1822.
   PubMed Web of Science ®Google Scholar
• Liu, Z., Zhang, Y., Hua, Y. F., Covey, J. M., Benbrook, D. M., Chan, K. K. (2008). Metabolism of a sulfur-containing heteroarotionoid antitumor agent, SHetA2, using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 22:3371–3381.
   PubMed Web of Science ®Google Scholar
• Masamha, C. P., Liu, T., Benbrook, D. M. (2007). SHetA2 targets cyclin D1 for proteasomal degradation through a GSK3β-independent mechanism leading to G1 cell cycle arrest. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 22–26, 2007, San Francisco, California, USA.
   Google Scholar
• Masamha, C. P., Benbrook, D. M. (2009). Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res 69:6565–6572.
   PubMed Web of Science ®Google Scholar
• Mic, F. A., Molotkov, A., Benbrook, D. M., Duester, G. (2003). Retinoid activation of RAR but not RXR is sufficient for mouse embryonic development. Proc Natl Acad Sci U S A 100:7135–7140.
   PubMed Web of Science ®Google Scholar
• Myers, T., Chengedza, S., Lightfoot, S., Pan, Y., Dedmond, D., Cole, L., et al. (2009). Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo. Invest New Drugs 27:304–318.
   PubMed Web of Science ®Google Scholar